Actuate Therapeutics Inc

Research Actuate Therapeutics Inc (ACTU) on Bullrun: market cap USD 37.80M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerACTU
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 37.80M
• Financial periodFY2025
• Net income-USD 22.23M

Valuation Snapshot

latest market cap is USD 37.80M.

About Actuate Therapeutics Inc

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.

Frequently asked questions

What is Actuate Therapeutics Inc's market cap?

Actuate Therapeutics Inc's market capitalization is USD 37.80M.

What does Actuate Therapeutics Inc do?

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.